Chronic fluoxetine induces a gradual desensitization of 5-HT1A receptors: Reductions in hypothalamic and midbrain Gi and Go proteins and in neuroendocrine responses to a 5-HT1A agonist

Journal of Pharmacology and Experimental Therapeutics

Volumn 279, Issue 2, 1996, Pages 1035-1042

  Li, Q ^a   Muma, N A ^a   Van De Kar, L D ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; CORTICOSTERONE; CORTICOTROPIN; FLUOXETINE; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; OXYTOCIN; SEROTONIN 1A RECEPTOR; SEROTONIN AGONIST;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DESENSITIZATION; DOSE TIME EFFECT RELATION; DRUG RECEPTOR BINDING; HORMONE RESPONSE; HUMAN; HYPOTHALAMUS; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MESENCEPHALON; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RAT; RECEPTOR SENSITIVITY; SEROTONINERGIC TRANSMISSION; SUBCUTANEOUS DRUG ADMINISTRATION;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ADRENOCORTICOTROPIC HORMONE; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOXETINE; FRONTAL LOBE; GTP-BINDING PROTEINS; HYPOTHALAMUS; MALE; MESENCEPHALON; OXYTOCIN; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS; SEROTONIN UPTAKE INHIBITORS;

EID: 0030433045     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. ADVOKAT, C. AND KUTLESIC, V.: Pharmacotherapy of the eating disorders: A commentary. Neurosci. Biobehav. Rev. 19: 59-66, 1995.
2. ARTIGAS, F., PEREZ, V. AND ALVAREZ, E.: Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch. Gen. Psychiatry 51: 248-251, 1994.
3. ARTIGAS, F.: Pindolol, 5-hydroxytryptamine, and antidepressant augmentation. Arch. Gen. Psychiatry 52: 969-971, 1995.
4. 1C receptors induces oxytocin release in the male rat. Brain Res. 611: 330-332, 1993.
5. 2 receptor agonist-induced oxytocin, prolactin, and corticosterone responses. Endocrinology 134: 1127-1131, 1994.
6. BLIER, P. AND BERGERON, R.: Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J. Clin. Psychopharmacol. 15: 217-222, 1995.
7. BLIER, P. AND DE MONTIGNY, C.: Current advances and trends in the treatment of depression. Trends Pharmacol. Sci. 15: 220-226, 1994.
8. BRILEY, M. AND MORET, C.: Neurobiological mechanisms involved in antidepressant therapies. Clin. Neuropharmacol. 16: 387-400, 1993.
9. 1A receptor antagonist WAY100635. Eur. J. Pharmacol. 264: 95-97, 1994.
10. 1A binding sites with G regulatory proteins. Biochem. Pharmacol. 39: 7-18, 1990.
11. 1A receptor to both adenylyl cyclase and phospholipase C is mediated via the same Gi protein. Cellular Signalling 3: 547-557, 1991.
12. 1A receptor antagonist. Behav. Brain Res. 73: 337-353, 1996.
13. FRANCOIS-BELLAN, A. -M., BOSLER, O., TONTON, M. -C., LIN-TONG, W. AND BEAUDET, A.: Association of neurotensin receptors with VIP-containing neurons and serotonin-containing axons in the suprachiasmatic nucleus of the rat. Synapse 10: 282-290, 1992.
14. 1A receptor subtype increases rat plasma ACTH concentration. Eur. J. Pharmacol. 147: 431-439, 1988.
15. 1A receptor agonist. Naunyn Schmiedebergs Arch. Pharmacol. 346: 121-126, 1992.
16. KELLY, J. S., LARKMAN, P., PENINGTON, N. J., RAINNIE, D. G., MCALLISTER-WILLIAMS, H. AND HODGKISS, J.: Serotonin receptor heterogeneity and the role of potassium channels in neuronal excitability. Adv. Exp. Med. Biol. 287: 177-191, 1991.
17. KOENIG, J. I., GUDELSKY, G. A. AND MELTZER, H. Y.: Stimulation of corticosterone and beta-endorphin secretion in the rat by selective 5-HT receptor subtype activation. Eur. J. Pharmacol. 137: 1-8, 1987.
18. KREISS, D. S. AND LUCKI, I.: Effect of acute and repeated administration of antidepressant drugs on extracellular levels of 5-hydroxytryptamine measured in vivo. J. Pharmacol. Exp. Ther. 274: 866-876, 1995.
19. LAM, R. W., GORMAN, C. P., MICHALON, M., STEINER, M., LEVITT, A. J., CORRAL, M. R., WATSON, G. D., MOREHOUSE, R. L., TAM, W. AND JOFFE, R. T.: Multicenter, placebo-controlled study of fluoxetine in seasonal affective disorder. Am. J. Psychiatry 152: 1765-1770, 1995.
20. 1A autoreceptors in rats treated with fluoxetine or paroxetine. Naunyn Schmiedebergs Arch. Pharmacol. 352: 141-148, 1995.
21. LECRUBIER, Y.: Antidepressant drugs: Similar but different? In New Pharmacological Approaches to the Therapy of Depressive Disorders, ed. by J. Mendlewicz, N. Brunello, S. Z. Lnger and G. Racagni, pp. 83-91, Karger, Basel, 1993.
22. 1A receptor responsivity in anxiety disorders and depression. Prog. Neuropsychopharmacol. Biol. Psychiat. 15: 723-733, 1991.
23. oα subunits. Eur. J. Pharmacol. 207: 361-364, 1991a.
24. 1A receptor responsivity in obsessive-compulsive disorder: Comparison of patients and controls. Arch. Gen. Psychiatry 48: 540-547, 1991b.
25. 12 subunit mRNA expression in rat brain. Eur. J. Pharmacol. Mol. Pharmacol. 227: 233-237, 1992a.
26. LESCH, K. P. AND MANJI, H. K.: Signal-transduction G proteins and antidepressant drugs: Evidence for modulation of α subunit gene expression in rat brain. Biol. Psychiatry 32: 549-579, 1992.
27. 1A receptor-effector system responsivity in panic disorder. Psychopharmacology 106: 111-117, 1992b.
28. 1A agonist ipsapirone by long-term treatment with fluoxetine, but not desipramine, in male rats. Biol. Psychiatry 36: 300-308, 1994.
29. 1A agonist 8-OH-DPAT in male rats. Brain Res. 630: 148-156, 1993.
30. LI, Y. -Q., ZENG, S. -L., DONG, Y. -X., RAO, Z. -R. AND SHI, J. -W.: Serotonin-, substance P- and tyrosine hydroxylase-like immunoreactive neurons projecting from the periaqueductal gray to the ventromedial hypothalamic nucleus in the rat. Neurosci. Lett. 134: 33-36, 1991.
31. LOWRY, O. H., ROSEBROUGH, W. Y., FARR, A. L. AND RANDALL, R. J.: Protein measurement with the folin phenol reagent. J. Biol. Chem. 193: 265-275, 1951.
32. MAMOUNAS, L. A., MULLEN, C. A., O'HEARN, E. AND MOLLIVER, M. E.: Dual serotoninergic projections to forebrain in the rat: Morphologically distinct 5-HT axon terminals exhibit differential vulnerability to neurotoxic amphetamine derivatives. J. Comp. Neurol. 314: 558-586, 1991.
33. MCCALLUM, J. F., WISE, A., GRASSIE, M. A., MAGEE, A. I., GUZZI, F., PARENTI, M. AND MILLIGAN, G.: The role of palmitoylation of the guanine nucleotide binding protein G11 alpha in defining interaction with the plasma membrane. Biochem. J. 310: 1021-1027, 1995.
34. 1A receptor-mediated regulation of plasma neuroendocrine hormones. J. Pharmacol. Exp. Ther. 271: 1246-1252, 1994.
35. MILLIGAN, G., PARENTI, M. AND MAGEE, A. I.: The dynamic role of palmitoylation in signal transduction. Trends Biochem. Sci. 20: 181-187, 1995.
36. MONTGOMERY, S. A.: Antidepressants in long-term treatment. Annu. Rev. Med. 48: 447-457, 1994.
37. o in neuroblastoma X glioma hybrid cells: Independent regulation during cyclic AMP-induced differentiation. J. Neurochem. 55: 1890-1898, 1990.
38. 1A agonists and antidepressants. J. Pharmacol. Exp. Ther. 260: 16-20, 1992.
39. o α-subunits in rat forebrain. Synapse 23: 246-257, 1996.
40. 1A receptor subtype in the paraventricular nuclei of the hypothalamus induces CRH ACTH release in the rat. Neuroendocrinology 56: 797-802, 1992.
41. 1A receptors in rat brain as assessed by neuroendocrine responses to 8-OH-DPAT stimulation. Soc. Neurosci. Abstr. 20: 1994.
42. 1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) in the rat. Pharmacol. Biochem. Behav. 33: 329-334, 1989.
43. sα. Biochemistry 32: 11064-11073, 1993.
44. RICHELSON, E.: Biological basis of depression and therapeutic relevance. J. Clin. Psychiatry 52: suppl. 6, 4-10, 1991.
45. ROSS, E. M.: Protein modification. Palmitoylation in G-protein signaling pathways. Curr. Biol. 5: 107-109, 1995.
46. ROTTER, J. J., GUNDLAH, C. AND AUEBBACH, S. B.: Increase in extracellular serotonin produced by uptake inhibitors is enhanced after chronic treatment with fluoxetine, Neurosci. Lett. 171: 183-186, 1994.
47. RUTTER, J. J., GUNDLAH, C. AND AUERBACH, S. B.: Systemic uptake inhibition decreases serotonin release via somatodendritic autoreceptor activation. Synapse 20: 225-223, 1995.
48. SMITH, G. S. T., SAVERY, D., MARDEN, C., COSTA, J. J. L., AVERILL, S., PRIESTLEY, J. V. AND RATTRAY, M.: Distribution of messenger RNAs encoding enkephalin, substance P, somatostatin, galanin, vasoactive intestinal polypeptide, neuropeptide Y, and calcitonin gene-related peptide in the midbrain periaqueductal grey in the rat. J. Comp. Neurol. 350: 23-40, 1994.
49. STEEL, R. G. D. AND TORRIE, J. H.: Principles and Procedures of Statistics with Special Reference to the Biological Sciences, McGraw-Hill, New York, 1960.
50. STERNLICHT, H. C.: Obsessive-compulsive disorder, fluoxetine and buspirone. Am. J. Psychiatry 150: 526, 1993.
51. STERNWEIS, P. C. AND ROBINSHAW, J. D.: Isolation of two proteins with high affinity for guanine nucleotides from membranes of bovine brain. J. Biol. Chem. 259: 13806-13813, 1984.
52. TOLLEFSON, G. D., RAMPEY, A. H., JR., POTVIN, J. H., JENIKE, M. A., RUSH, A. J., DOMINGUEZ, R. A., KORAN, L. M., SHEAR, M. K., GOODMAN, W. AND GENDUSO, L. A.: A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch. Gen. Psychiatry 51: 559-567, 1994.
53. VAN DE KAR, L. D. AND BROWNFIELD, M. S.: Serotonergic neurons and neuroendocrine function. NIPS 8: 202-207, 1993.
54. 1A receptor synthetic peptides. Mechanisms of adenylyl cyclase inhibition. J. Biol. Chem. 269: 16720-16725, 1994.
55. 1A antagonist WAY-100635 inhibits the 8-OH-DPAT induced increase in plasma ACTH, corticosterone and oxytocin but not prolactin (Abstract). Soc. Neurosci. 22: 1996.
56. WILLOUGHBY, J. O. AND BLESSING, W. W.: Origin of serotonin innervation of the arcuate and ventromedial hypothalamic region. Brain Res. 418: 170-173, 1987.
57. WONG, D. T., BYMASTER, F. P. AND ENGLEMAN, E. A.: Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: Twenty years since its first publication. Life Sci. 67: 411-441, 1995.